Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 mars 2020 05h18 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
24 févr. 2020 02h05 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present at 9th Annual SVB Leerink Global Healthcare Conference

SINGAPORE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company, today announced its...
05 déc. 2019 18h22 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter’s Option to Purchase Additional ADSs

SINGAPORE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the closing...
03 déc. 2019 01h00 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has...
02 déc. 2019 12h50 HE | Source: ASLAN PHARMACEUTICALS LIMITED

Aslan Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

SINGAPORE, Dec. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has...
02 déc. 2019 02h07 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%....
22 nov. 2019 01h30 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical...
11 nov. 2019 03h21 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
31 oct. 2019 03h37 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
22 oct. 2019 02h45 HE | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability...

Page précédente